JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Aktien・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

19.68 -0.46

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.24

Max

19.95

Schlüsselkennzahlen
By Trading Economics
Einkommen	801K 57M
Verkäufe	-399K 141M
KGV Branchendurchschnitt	13.497 34.393
Gewinnspanne	40.119
Angestellte	181
EBITDA	526K 73M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+55.09% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-379M 2.7B
Vorheriger Eröffnungskurs	20.14
Vorheriger Schlusskurs	19.68

Nachrichtenstimmung

By Acuity

53%

47%

307 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

N/A / 24.28 Unterstützung & Widerstand

Catalyst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2025, 17:49 UTC

Wichtige Markttreiber

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. Aug. 2025, 17:18 UTC

Wichtige Markttreiber

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. Aug. 2025, 16:25 UTC

Ergebnisse

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. Aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. Aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. Aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. Aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement 2Q Rev $25.8M >EXOD

11. Aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. Aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. Aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. Aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. Aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. Aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. Aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. Aug. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. Aug. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Says Sabadell Offer Remains in Effect

11. Aug. 2025, 16:26 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Announced TSB Sale on July 1

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer-Vergleich

Kursveränderung

Catalyst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

55.09% Vorteil

12-Monats-Prognose

Durchschnitt 30.8 USD 55.09%

Hoch 35 USD

Tief 22 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Catalyst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Catalyst Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 24.28Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Stimmung

By Acuity

307 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.